Welcome to our dedicated page for RETINALGENIX TECHNOLOGIES SEC filings (Ticker: RTGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-trial spending buried in footnotes? FDA risk factors scattered across dozens of pages? RetinalGenix Technologies’ SEC documents can be daunting because they blend medical-device regulations, telehealth revenue disclosures and pharmaco-genetic research updates.
Stock Titan solves that problem. Our AI reviews every RetinalGenix annual report 10-K simplified, flags pivotal trial milestones inside the Management’s Discussion section, and converts accounting jargon into plain language. Real-time alerts surface RetinalGenix Form 4 insider transactions the moment executives buy or sell shares, turning raw filings into actionable context.
Use the menu to jump directly to what matters:
- 10-Q access: Want the latest RetinalGenix quarterly earnings report 10-Q filing? We link cash-burn tables to AI-generated trend graphics.
- Form 4 monitoring: Track RetinalGenix insider trading Form 4 transactions and receive push updates for every executive stock move.
- 8-K clarity: Our summaries make RetinalGenix 8-K material events explained in minutes, not hours.
- Proxy deep-dives: Quickly compare R&D incentives with the RetinalGenix proxy statement executive compensation dashboard.
The entire archive—10-K, 10-Q, 8-K, S-1, plus RetinalGenix executive stock transactions Form 4—updates in real time from EDGAR. Already scrolling through footnotes? Try understanding RetinalGenix SEC documents with AI; our highlights point you straight to patent data, licensing revenue breakdowns and clinical-trial timelines.
Whether you need a quick RetinalGenix earnings report filing analysis before market open or a deep study of device-approval risk, everything is here—explained simply and delivered the moment it’s filed.
RetinalGenix Technologies (RTGN) filed its Q3 2025 10‑Q, reporting no revenue and a smaller quarterly net loss of
Liquidity is strained: cash was
For the nine months, net loss improved to
RTGN: A shareholder filed a Form 144 notice to sell up to 77,400 common shares with an aggregate market value of $247,680.00. The filing lists Alpine Securities Corporation as broker and targets an approximate sale date of November 10, 2025 on the OTCQB.
The filing notes 18,604,961 shares outstanding. It also discloses prior acquisitions and recent activity: the securities were acquired via warrant exercise dated 09/01/2018, with payment by check on 03/06/2019. Over the past three months, Bayern Capital LLC reported sales of common shares, including 8,000 for $30,718.67 on 10/24/2025, 10,100 for $36,800.27 on 10/27/2025, and 2,500 for $8,063.95 on 10/31/2025.
FAQ
What is the current stock price of RETINALGENIX TECHNOLOGIES (RTGN)?
What is the market cap of RETINALGENIX TECHNOLOGIES (RTGN)?
